| Literature DB >> 27812386 |
Mattia Arrigo1, Heli Tolppanen1, Malha Sadoune1, Elodie Feliot1, Antonio Teixeira2, Said Laribi3, Patrick Plaisance4, Semir Nouira5, Mehmet Birhan Yilmaz6, Etienne Gayat7, Alexandre Mebazaa7.
Abstract
AIMS: Acute heart failure (AHF) is one of the leading causes of unscheduled hospitalization and is associated with frequent readmissions and substantial mortality. Precipitating factors of AHF influence short-term mortality, but their effect on outcome after hospital discharge is unknown. The present study assessed the effect of precipitating factors on readmission and long-term survival in the overall population and in patients aged 75 years or younger. METHODS ANDEntities:
Keywords: Acute heart failure; Mortality; Precipitating factor; Pulmonary disease; Readmission
Year: 2016 PMID: 27812386 PMCID: PMC5066631 DOI: 10.1002/ehf2.12083
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Baseline characteristics at admission of patients with AHF
| Clinical characteristics | All patients ( | Precipitating factor |
| ||
|---|---|---|---|---|---|
| No acute pulmonary disease ( | Acute pulmonary disease ( | ||||
| Demographics | Age (years) | 75 (64–84) | 78 (66–88) | 73 (64–82) | 0.001 |
| Male gender | 425 (56%) | 73 (49%) | 352 (58%) | 0.053 | |
| Clinical signs | SBP (mmHg) | 140 (120–162) | 140 (114–161) | 140 (120–162) | 0.613 |
| DBP (mmHg) | 80 (68–93) | 75 (65–90) | 80 (70–94) | 0.007 | |
| Heart rate (per min) | 88 (72–105) | 90 (76–112) | 87 (72–105) | 0.067 | |
| Respiratory rate (per min) | 26 (22–32) | 29 (24–34) | 26 (22–32) | < 0.001 | |
| Oxygen saturation (%) | 95 (90–97) | 93 (88–96) | 95 (91–97) | < 0.001 | |
| Rales | 582 (82%) | 118 (87%) | 464 (81%) | 0.081 | |
| Wheezing | 144 (19%) | 65 (44%) | 79 (13%) | < 0.001 | |
| Jugular distension | 310 (41%) | 54 (36%) | 256 (42%) | 0.194 | |
| Peripheral edema | 431 (57%) | 77 (52%) | 354 (58%) | 0.140 | |
| Temperature (°C) | 36.9 (36.5–37.2) | 37 (36.5–37.5) | 36.8 (36.5–37.1) | < 0.001 | |
| Height (cm) | 168 (160–173) | 167 (159–171) | 168 (160–173) | 0.058 | |
| Weight (kg) | 73 (63–85) | 75 (62–88) | 72 (63–85) | 0.880 | |
| Comorbidities | |||||
| Chronic heart failure | 358 (47%) | 67 (45%) | 291 (48%) | 0.523 | |
| Coronary artery disease | 246 (33%) | 55 (37%) | 191 (32%) | 0.207 | |
| Prior PCI/CABG | 93 (12%) | 18 (12%) | 75 (12%) | 1.000 | |
| Peripheral vascular disease | 78 (10%) | 14 (9.4%) | 64 (11%) | 0.765 | |
| Valve disease | 97 (13%) | 15 (10%) | 82 (14%) | 0.278 | |
| Atrial fibrillation or flutter | 286 (38%) | 61 (41%) | 225 (37%) | 0.398 | |
| Hypertension | 520 (69%) | 103 (69%) | 417 (69%) | 1.000 | |
| Diabetes mellitus | 274 (36%) | 51 (34%) | 223 (37%) | 0.570 | |
| Dyslipidemia | 205 (27%) | 34 (23%) | 171 (28%) | 0.217 | |
| Obesity | 78 (10%) | 16 (11%) | 62 (10%) | 0.881 | |
| Active or recent smoking | 137 (18%) | 31 (21%) | 106 (18%) | 0.344 | |
| COPD or asthma | 132 (18%) | 62 (42%) | 70 (12%) | < 0.001 | |
| Chronic kidney disease | 106 (14%) | 21 (14%) | 85 (14%) | 1.000 | |
| Depression | 28 (3.7%) | 8 (5.4%) | 20 (3.3%) | 0.230 | |
| Cognitive dysfunction | 39 (5.2%) | 8 (5.4%) | 31 (5.1%) | 0.838 | |
| Loss of autonomy | 21 (2.8%) | 11 (7.4%) | 10 (1.7%) | 0.001 | |
| Chronic liver disease | 13 (1.7%) | 4 (2.7%) | 9 (1.5%) | 0.299 | |
| Active or recent cancer | 70 (9.3%) | 13 (8.7%) | 57 (9.4%) | 0.876 | |
| Anaemia | 37 (4.9%) | 8 (5.4%) | 29 (4.8%) | 0.832 | |
| Chronic treatment | Betablockers | 310 (41%) | 61 (41%) | 249 (41%) | 1.000 |
| ACE‐I or ARB | 417 (55%) | 77 (52%) | 340 (56%) | 0.358 | |
| MRA | 104 (14%) | 16 (11%) | 88 (14%) | 0.288 | |
| Diuretics | 433 (57%) | 90 (60%) | 343 (57%) | 0.407 | |
| Antiplatelets | 304 (40%) | 67 (45%) | 237 (39%) | 0.193 | |
| Biology | BNP (pg/mL) | 1082 (611–2190) | 899 (404–1445) | 1191 (643–2329) | <0.001 |
| Troponin I (µg/L) | 0.05 (0.02–0.129) | 0.05 (0.02–0.2) | 0.05 (0.02–0.12) | 0.403 | |
| Troponin T (µg/L) | 0.02 (0.01–0.11) | 0.04 (0.01–0.2) | 0.01 (0.01–0.11) | 0.787 | |
| Creatinine (µmol/L) | 108 (78–146) | 106 (79–146) | 108 (78–146) | 0.838 | |
| eGFR (Cockroft) | 51.5 (34.9–75) | 49.3 (32.4–69.2) | 51.6 (35–75) | 0.614 | |
| CRP (mg/L) | 16 (6–42) | 35 (10–110) | 14 (5–31) | < 0.001 | |
| Procalcitonin (µg/L) | 0.12 (0.08–0.22) | 0.16 (0.12–0.36) | 0.11 (0.08–0.16) | 0.013 | |
ACE‐I, angiotensin converting enzyme inhibitor; AHF, acute heart failure; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRP, c‐reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
Figure 1Levels of BNP and CRP (C‐reactive protein) at admission in the group of patients with acute heart failure precipitated by acute pulmonary disease (n = 149) compared with acute heart failure precipitated by non‐pulmonary causes (n = 606). Median and 95% confidence interval are displayed.
Precipitating factors and risk of 90 days readmission
| Overall, unadjusted | Overall, adjusted | Patients ≤75 years, adjusted | Patients >75 years, adjusted | |||||
|---|---|---|---|---|---|---|---|---|
| Precipitating factor | HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
|
| Atrial fibrillation | 1.29 (0.83–2.00) | 0.25 | 1.46 (0.93–2.29) | 0.10 | 2.23 (1.29–3.85) | 0.004 | 0.74 (0.33–1.67) | 0.47 |
| Acute coronary syndrome | 1.38 (0.70–2.72) | 0.35 | 1.36 (0.66–2.79) | 0.40 | 2.23 (1.02–4.86) | 0.044 | 0.34 (0.05–2.51) | 0.29 |
| Acute pulmonary disease | 0.61 (0.37–0.99) | 0.049 | 0.65 (0.39–1.08) | 0.10 | 0.20 (0.06–0.63) | 0.006 | 1.36 (0.72–2.56) | 0.35 |
| Other | 1.12 (0.78–1.62) | 0.54 | 0.99 (0.68–1.44) | 0.95 | 0.98 (0.60–1.59) | 0.92 | 1.02 (0.56–1.85) | 0.95 |
AHF, acute heart failure; CI, confidence interval.
Risk of 90 days readmission in presence of predefined classes of precipitating factors of AHF compared with absence of the same factor. Adjustment was performed for age, sex and impaired renal function.
Figure 2Readmissions of patients with acute heart failure precipitated by acute pulmonary disease compared with acute heart failure precipitated by non‐pulmonary causes during 90 days after discharge in the overall population and in the subgroup of patients ≤75 years.
Precipitating factors and risk of 1 year mortality
| Overall unadjusted | Overall adjusted | Patients ≤75 years, adjusted | Patients >75 years, adjusted | |||||
|---|---|---|---|---|---|---|---|---|
| Factor | HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
|
| Atrial fibrillation | 0.66 (0.36–1.21) | 0.18 | 0.63 (0.34–1.15) | 0.13 | 0.50 (0.12–2.16) | 0.35 | 0.67 (0.34–1.31) | 0.24 |
| Acute coronary syndrome | 0.96 (0.42–2.19) | 0.92 | 1.00 (0.44–2.29) | 1.00 | ‐‐ | 0.98 | 1.49 (0.64–3.46) | 0.35 |
| Acute pulmonary disease | 1.59 (1.04–2.43) | 0.034 | 1.46 (0.94–2.25) | 0.09 | 2.52 (1.17–5.41) | 0.018 | 1.03 (0.61–1.75) | 0.91 |
| Other | 0.90 (0.60–1.33) | 0.59 | 0.95 (0.64–1.43) | 0.82 | 0.72 (0.35–1.50) | 0.38 | 1.06 (0.66–1.71) | 0.81 |
AHF, acute heart failure; CI, confidence interval.
Risk of 1 year mortality in presence of predefined classes of precipitating factors of AHF compared with absence of the same factor. Adjustment was performed for age, sex and impaired renal function.
No risk calculation possible because of lack of events in this subgroup.
Figure 3Mortality of patients with acute heart failure precipitated by acute pulmonary disease compared with acute heart failure precipitated by non‐pulmonary causes during 1 year after admission in the overall population and in the subgroup of patients ≤75 years.